Randomized Trial of Vaginal Self Sampling for Human Papillomavirus (HPV)
Randomized Controlled Trial of Vaginal Self Sampling for Human Papillomavirus to Increase Cervical Cancer Screening Participation
Sponsor: Juravinski Cancer Centre Foundation
This PHASE2/PHASE3 trial investigates Cervical Intraepithelial Neoplasia and Human Papillomavirus Infection and is currently ongoing. Juravinski Cancer Centre Foundation leads this study, which shows 6 recorded versions since 2010 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2/PHASE3
Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2_PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE2_PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Unknown Status PHASE2_PHASE3
Status: Enrolling By Invitation → Unknown Status
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Enrolling By Invitation PHASE2_PHASE3
First recorded
Apr 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Juravinski Cancer Centre Foundation
- McMaster University
- Merck Frosst Canada Ltd.
- Public Health Agency of Canada (PHAC)
For direct contact, visit the study record on ClinicalTrials.gov .